During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

Actinium Pharmaceuticals (ATNM) announced a clinical program comprising of trials studying Actimab-A in combination with either Keytruda – ...

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...